TMEM44: A Transmembrane Protein Extremely Regulated by Signaling Pathways

Target Name: TMEM44

NCBI ID: G93109

TMEM44

TMEM44: A Transmembrane Protein Extremely Regulated by Signaling Pathways

Introduction

TMEM44 (Transmembrane protein 44), also known as cullin 3 (CAL3), is a highly conserved transmembrane protein that plays a crucial role in various signaling pathways. It is a key regulator of the T-cell receptor (TCR) signaling pathway, which is involved in cell recognition and proliferation. TMEM44 is highly regulated by signaling pathways, including TCR signaling, DNA double-strand repair, and apoptosis.

Expression and Localization

TMEM44 is highly expressed in most tissues, including the brain, heart, and gastrointestinal tract, and has been shown to be involved in various physiological processes, including cell survival, migration, and invasion. TMEM44 is predominantly expressed in the endoplasmic reticulum (ER) and has been shown to be involved in protein folding and localization.

TMEM44 functions as a negative regulator of the TCR signaling pathway. It is part of the TCR complex and is involved in the negative regulation of CD4+ T-cell activation and proliferation. TMEM44 has been shown to interact with the TCR浼? chain and prevent it from engaging to the Fc portion of the antibody. This interaction between TMEM44 and TCR浼? is critical for the regulation of TCR signaling.

TMEM44 is also involved in the regulation of DNA double-strand repair. It has been shown to be involved in the repair of DNA double-strand breaks in response to DNA damage, such as those caused by UV radiation or chemicals. TMEM44 has also been shown to be involved in the regulation of apoptosis, which is a critical mechanism for cell death and regeneration.

TMEM44 is also involved in the regulation of various signaling pathways, including the PI3K/AKT signaling pathway, which is involved in cell survival and metabolism. TMEM44 has also been shown to be involved in the regulation of the NF-kappa-B signaling pathway , which is involved in inflammation and immune response.

Drug Targeting and Biomarkers

TMEM44 has been identified as a potential drug target for various diseases, including cancer, autoimmune diseases, and neurodegenerative diseases (11, 12). The TCR signaling pathway is a key target for many therapeutic drugs, including anti-cancer drugs, and TMEM44 is involved in this pathway, making it an attractive target for cancer therapy.

In addition to its role in the TCR signaling pathway, TMEM44 is also involved in the regulation of DNA double-strand repair, which is a critical mechanism for the regulation of cancer cell survival. Therefore, TMEM44 may also be an attractive biomarker for the diagnosis and evaluation of cancer.

Conclusion

TMEM44 is a transmembrane protein that is highly conserved and involved in various signaling pathways, including TCR signaling, DNA double-strand repair, and apoptosis. It is expressed in most tissues and functions as a negative regulator of the TCR signaling pathway. TMEM44 has also has been shown to be involved in the regulation of DNA double-strand repair and apoptosis. As a potential drug target, TMEM44 is an attractive target for cancer therapy and may also be an attractive biomarker for the diagnosis and evaluation of cancer.

Protein Name: Transmembrane Protein 44

The "TMEM44 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TMEM44 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets